Symphera, an EIC Accelerator Winner, Swaps Tools Inside the Body

A keyhole operation is done through a handful of ports in the abdomen, and each time the surgeon needs scissors instead of a grasper, or a hook to cauterise, one instrument comes out of the body and another goes in. Symphera, a Munich start-up registered in 2023, builds a single handheld instrument that holds several tool tips in a rotating barrel and swaps them inside the patient at the push of a button. The company's website says a single procedure "can involve dozens of tool changes" and that its aim is to make them obsolete.

The EIC Accelerator selected the project at its March 2025 cut-off for blended finance. CORDIS records a grant agreement for €2,492,700 running from 1 November 2025 to 31 October 2027, with the aim of conducting in-human trials, finalising the design and scaling manufacturing for clinical and regulatory submissions. One year into that period, the public evidence is a bench study on animal tissue, a patent family and a company that, by its own statement, has no cleared product.

One shaft, a barrel of tips

The device is described in most detail not by the company but in a study in Surgical Endoscopy, published online on 3 November 2025 and openly available through Europe PMC. The prototype tested there, internal version 4.2 and the fourth generation, fits through an 8 mm trocar, weighs about 300 g and is 54 cm long with a 31 cm shaft. Pressing a button on the handle retracts the current tip, rotates an internal barrel with up to eight preconfigured tip positions and pushes the chosen tip back out, all without moving the instrument. A screen shows which tip is selected.

The standard alternative is not a single competing product but the way laparoscopy is done today: separate instruments, each withdrawn and replaced through the port. The paper's authors argue that the device also reduces reliance on assistant staff. Symphera's patent family, which includes US application 20260123950 with a priority date of 15 January 2024 and inventors Philipp Preißler and Thomas Wegele, claims a motor-driven magazine of interchangeable tips mounted on a laparoscopic shaft. It is an application published in May 2026, not a granted patent.

The bench test, and who ran it

Seven surgeons at the IRCAD training centre in Strasbourg, six general surgeons and one gynaecologist with 6 to 30 years of experience, used the prototype for three standard tasks on excised pig stomach tissue in a torso trainer: cutting and moving squares of tissue, cutting along a line with scissors and a monopolar hook, and a combined targeting task. According to the paper, all participants completed the tasks with no safety concerns across 148 tool changes, and the time spent changing tools had no significant effect on overall task duration.

The same paper reports the failures plainly: tool-changing errors in 4.73% of changes and software errors that required a reboot in 6.08%. Ergonomics were rated moderate, and the two female participants raised the weight and comfort of the device. The authors conclude that the prototype "was safe, functional, and well-received" but that software instability and ergonomic refinements remain necessary.

What the EIC grant has to deliver

The CORDIS objective gives no numbers: no target change time, no number of patients and no date for regulatory filing. It names the steps instead: testing in simulated operating environments, finalising the design, in-human trials to validate safety and efficacy, and manufacturing scale-up. CORDIS lists no total project cost and no periodic report so far. Symphera's own announcement of the award gives no amount and says the money goes to engineering and validation towards verification and regulatory submission.

1. Working in-body tool switchingPrototype148 changes on animal tissue in the 2025 study, which predates the grant's start.
2. Stable software and better ergonomicsNot yet shownThe study found reboots in 6.08% of changes; no later test is published.
3. In-human trialsNot yet shownNo trial announcement on the company's news page or in web searches by 28 October 2026.
4. Regulatory submissionNot yet shownThe company says the device is investigational and not cleared by any authority.

Grant money on top of a seed round

Symphera announced a €2.4 million seed round on 16 September 2024, led by High-Tech Gründerfonds, as reported by Tech.eu and Munich Startup, for product development and first preclinical studies. One outlet, Tech Funding News, headlined the round as €2.5 million while giving €2.4 million in its text. Bayern Kapital lists the company in its portfolio without an amount.

The North Data entry for the company shows two further public awards: €524,900 of Bavarian state aid under the BayTOU programme for technology-oriented start-ups, dated 23 April 2025, and €566,421 from 1 February 2026 for a subproject of ERICH, a federally funded project on automated instrument changes in robotic surgery, to research an end effector. The company's website says an earlier project, Viable Surgery, was funded under the federal EXIST programme until April 2024.

The award was for blended finance, which can include an equity investment by the EIC Fund. A page for Symphera GmbH exists at the address of the EIC Fund portfolio, but it returned "Access denied" when checked on 28 October 2026, and no investment amount or date appears in the company's news or on the EIC Fund's public pages. The filed accounts are not freely displayed, so no revenue, loss or staff figure is public.

The route to market runs through two regulators

To be sold in the EU, a surgical instrument needs CE marking under the Medical Device Regulation, and in the United States it needs FDA clearance or approval. Symphera says it was accepted into the FDA's Safer Technologies Program, which offers closer interaction with the agency for devices expected to be significantly safer than current treatment; no FDA record of Symphera's participation turned up in web searches, so the claim rests on the company's statement. Participation is not a clearance. In September 2025 the company named Brett Parker, an assistant professor of surgery at Johns Hopkins, as a clinical advisor for clinical strategy and workflow evaluations.

For the EU, Symphera is a European developer of surgical instruments at the start of the regulated path, backed by German federal, Bavarian and EU public money and by private investors including IRCAD of Strasbourg. The 2026 ERICH funding extends the work towards robotic surgery, which the 2024 seed announcement named as a further possible application.

Symphera has not been asked for comment for this article. The reporting is based on publicly available sources, listed below.